he association between increased serum uric acid (SUA) levels and cardiovascular risk has been debated for over 50 years. 1 Several large studies have provided conflicting results regarding the clinical significance of elevated SUA levels in cardiovascular or cerebrovascular disease. Some concluded that SUA is an independent risk factor for cardiovascular disease (CVD), [2] [3] [4] [5] [6] with an apparently stronger association in women than in men, 7, 8 in the elderly 9 and in patients with essential hypertension, 10 congestive heart failure 11, 12 and type 2 diabetes mellitus. 13, 14 In contrast, the Framingham Heart Study concluded that an association with CVD merely reflects the link between SUA and other risk factors, including hypertension, renal disease, elevated lipoprotein levels and the use of diuretics. 15 In vitro and in vivo studies have shown uric acid (UA) to be a powerful free radical scavenger and, paradoxically, these antioxidant properties would be expected to provide a number of benefits within the cardiovascular system. 16 Furthermore, elevated SUA levels may induce renal disease, 17 which seems to progress in parallel with CVD. 18 Several mechanisms by which SUA could have a direct pathogenic role in CVD have also been suggested. 16 Therefore, it is unclear whether high SUA promotes or protects against the development of CVD, or simply acts as a passive marker of increased risk.
In the present study we examined the association of UA concentrations with the clinical outcome and the fatality rate of patients with acute stroke.
lipidemia was defined as total cholesterol >200 mg/dl (5.17 mmol/L) and high-density lipoprotein-cholesterol (HDL-C) <40 mg/dl (1.03 mmol/l) for men and <50 mg/dl (1.29 mmol/L) for women or prescribed lipid-lowering medication. Individuals classified as smokers included current smokers (defined as those who smoked at least 10 cigarettes per day for 6 months or more and those who smoked daily for 1 year or more regardless of the number of cigarettes per day) and those who had been ex-smokers and had quit more than 1 year ago. Alcohol abuse was defined as drinking more than 5 drinks per day (1 drink defined as 12 g of alcohol). Coronary heart disease was defined as history of Q or non-Q myocardial infarction or percutaneous transluminal coronary angioplasty or coronary artery bypass graft. Congestive heart failure was defined as history of dyspnea on ordinary exertion, paroxysmal nocturnal dyspnea or acute pulmonary edema or the presence of distended neck veins (in other than the supine position and in absence of venous obstruction), bilateral ankle edema (not caused by a condition other than cardiac failure), hepatomegaly (not because of liver disease), rales in the absence of pulmonary disease, positive S3, or chest radiographic evidence of pulmonary congestion (pleural fluid, pulmonary venous congestion, prominent pulmonary veins) with or without cardiomegaly. Previous stroke was defined as history of hospitalization for a syndrome of rapidly developing clinical signs of focal or global disturbance lasting for 24 h or longer, attributed to ischemic or hemorrhagic lesions in the brain and verified with computed tomography (CT) scan or MRI.
We recorded systolic and diastolic blood pressures, as well as pulse rate, on admission. Routine laboratory investigations were performed the first day after admission to hospital after overnight fasting, and included levels of glucose, total cholesterol, HDL-C and low-density lipoprotein-cholesterol (LDL-C) subfractions, triglycerides, urea, creatinine, UA, hemoglobin, hematocrit and erythrocyte sedimentation rate.
All patients underwent a CT brain scan. Stroke types were classified into ischemic stroke and intracerebral hemorrhage (ICH). All patients received treatment according to the current guidelines but none of them underwent thrombolysis or surgical treatment. [19] [20] [21] On discharge from hospital, the length of stay and the occurrence and causes of death were recorded.
The results are expressed as percentages for categorical variables and as mean ± standard deviation or as median and interquartile range (IQR) for continuous variables. The chi-square and Kruskal-Wallis tests were used to compare respective categorical and continuous variables between groups. Associations between continuous variables were explored using Spearman's rank order correlation coefficient. Using multiple logistic regression analysis, we assessed the effect of SUA concentration on acute stroke outcome after controlling for clinical variables that differed significantly between groups in the univariate analysis or that are already established as predictors of stroke.
Because in-hospital mortality has the weakness that it is not measured at a consistent time point following stroke onset, we also analyzed mortality via survival analysis. For the univariate analysis, we compared Kaplan-Meier survival curves using the log-rank test. Multiple Cox proportionalhazards analysis was then used to assess the association between SUA level and death rates after correction for factors known to influence acute stroke outcome. In all cases, a 2-tailed p-value less than 0.05 was considered significant. All statistical analyses were performed with the SPSS software (version 10.0; SPSS Inc, Chicago, IL, USA).
Results
A total of 435 patients with stroke, 210 (48.3%) men and 225 (51.7%) women, with a median age of 75 years (IQR, 70-82 years), were included in the present study. Three hundred and eighty (87.4%) of them experienced an ischemic stroke and 55 (12.6%) had an ICH. Table 1 lists the demographics, the vascular risk factors and vascular diseases of the study population. The most prevalent vascular risk factors were hypertension and hyperlipidemia, which were present in 77.7% and 57.9%, respectively, of the patients. A significant proportion of the study population, rising up to 39.5%, had experienced another stroke in the past, and 23.2% of them also suffered from ischemic heart disease. There were no significant differences in the prevalence of vascular risk factors or concomitant vascular diseases between patients with ischemic stroke and those with ICH. Table 2 lists the clinical and laboratory findings at admission. Patients with ICH had significantly higher systolic and diastolic blood pressures at admission compared with patients with ischemic stroke (p<0.005 and p<0.01, respectively). There were no other significant differences in the clinical or laboratory findings at admission between patients with ischemic stroke and those with ICH.
As shown in Table 3 , a significantly higher concentration of SUA was associated with male sex and the presence of congestive heart failure. SUA positively correlated with urea (r=0.26, p<0.001) and creatinine (r=0.36, p<0.001) and negatively with LDL-C (r=-0.20, p<0.05) and HDL-C (r=-0.23, p<0.01). Median duration of hospitalization was 7 days (IQR, 5-9 days; range, 1-31 days). Duration of hospitalization was significantly longer for patients with ICH compared with patients with ischemic stroke (p=0.001). Table 4 lists the outcomes of the study population. Overall fatality during hospitalization was 14.3%; case fatality for ischemic stroke was 11.6% and for ICH, 32.7% (p<0.001). Deaths were caused by incident stroke (n=28), cardiovascular causes (myocardial infarction and cardiac arrhythmia) (n=15), pneumonia (n=16) and other causes (n=3). Death occurred after a median of 4 days (IQR, 2-7 days; range, 1-25 days) after admission. As shown in Table 5 , on univariate analysis death was associated with older age, smoking, presence of congestive heart failure or atrial fibrillation, absence of hyperlipidemia, and ICH as the index event.
As shown in Table 6 , on univariate analysis, glucose, urea, creatinine and UA at admission were significantly higher in patients who died, whereas total cholesterol and HDL-C were significantly lower. Univariate survival analysis using the log-rank test yielded similar findings, except that the presence of hypertension also had a hazard ratio greater than 1, indicating an increased risk of death.
On multiple logistic regression analysis, the independent relationship between higher SUA levels on admission and death was confirmed (odds ratio (OR) 1.37; 95% confidence interval (CI), 1.13-1.67; p=0.001). In addition to SUA, the only other variables independently associated with death were urea level (OR, 1.03; 95% CI, 1.02-1.04; p<0.001) and the presence of atrial fibrillation (OR, 4.27; 95% CI, 1.62-11.23; p<0.005). Multiple Cox proportional-hazards analysis yielded similar relationships between death and SUA level (hazard ratio, 1.28; 95% CI, 1.11-1.48; p= 0.001), urea level (hazard ratio, 1.02; 95% CI, 1.01-1.03; p<0.001), and presence of atrial fibrillation (hazard ratio, 2.69; 95% CI, 1.19-6.04; p<0.05).
In order to determine the sensitivity and specificity of SUA at predicting early mortality after stroke, a receiveroperator characteristics curve was plotted (area 0.700, 95% CI 0.607-0.792). Using a cut-off value of 4.95 mg/dl (0.29 mmol/L), the test was 78% sensitive, but only 39% specific. However, if the patient's urate was greater than or equal to 7.85 mg/dl (0.47 mmol/L), then there would be a high probability of early death from stroke (positive predictive value =87%), although the test's sensitivity would fall to 51%.
We also performed similar analyses in order to identify the variables that could predict each specific cause of death. On multiple logistic regression analysis, the only variables independently associated with death attributed directly to the initial stroke were SUA level (OR, 1.96; 95% CI, 1.46-2.64; p<0.001), urea level (OR, 1.02; 95% CI, 1.01-1.03; p<0.05) and presence of atrial fibrillation (OR, 3.58; 95% CI, 1.01-12.67; p<0.05). In contrast, there were no differences in SUA levels at admission between patients who died from cardiovascular causes, pneumonia or other causes and those who did not. However, when deaths from incident stroke and cardiovascular causes were analyzed together, these patients had higher SUA levels at admis- Finally, we evaluated the predictive value of SUA on the occurrence of death in the various ischemic stroke subtypes. Among the 380 patients with ischemic stroke, 117 (30.8%) had atrial fibrillation and were considered to have suffered a cardioembolic stroke and the remaining 263 patients with ischemic stroke (69.2%) were considered to have suffered a non-cardioembolic stroke. Case fatality for ischemic cardioembolic stroke was 23.1% and for ischemic non-cardioembolic stroke, 6.5% (p<0.001). Case fatality did not differ between ischemic cardioembolic stroke and ICH (23.1% vs 32.7%, p=0.25), but was significantly lower for ischemic non-cardioembolic stroke compared with ICH (6.5% vs 32.7%, p<0.001). There were no differences in SUA levels between patients with cardioembolic and non cardioembolic ischemic stroke. In patients with ischemic stroke (n=380), death was associated on multiple logistic regression analysis with the same variables as in the whole population [SUA (OR, 1.36; 95% CI, 1.10-1.68; p<0.005), urea level (OR, 1.03; 95% CI, 1.02-1.05; p<0.001) and presence of atrial fibrillation (OR, 5.53; 95% CI, 1.86-16.44; p<0.005)]. In patients with cardioembolic or non-cardioembolic ischemic stroke, death was associated on multiple logistic regression analysis only with urea level (OR, 1.04; 95% CI, 1.02-1.06; p<0.001 and OR, 1.02; 95% CI, 1.01-1.04; p<0.005 respectively). We did not perform multiple regression analysis in patients with ICH because there was only a small number of patients in this subgroup (n=55).
Discussion
In the present study elevated levels of SUA were independently associated with an increased risk of early death in patients with acute stroke, particularly death attributed to incident stroke or from cardiovascular causes. Although SUA has been found to be an independent predictor of stroke, 22, 23 there are few studies showing that SUA independently predicts poor outcome in stroke patients. Weir et al found in 2,498 patients admitted with acute stroke that the admission SUA level independently predicted worse outcome and a higher rate of repeated stroke or other cardio- vascular events. 24 Others have also reported that elevated SUA levels in patients with acute stroke are strongly associated with poorer outcome. 25, 26 Experimental evidence could explain how UA may play a pathogenetic role in stroke. Hypertension is a powerful predictor of stroke, 27, 28 and UA is commonly associated with hypertension. 29, 30 Elevated SUA level is an independent predictor of hypertension and is present in 25% of patients with new-onset, untreated primary hypertension. 31 The increase in the SUA level may be caused by the decrease in renal blood flow that usually accompanies the hypertensive state, because a low renal blood flow stimulates urate reabsorption. 32 Experimentally-induced hyperuricemia also increased the blood pressure in rats by a renal mechanism linked to inhibition of nitric oxide (NO), activation of the renin -angiotensin system, and development of renal arteriosclerosis. 33 Once renal arteriosclerosis develops, the kidney plays a major role in the maintenance of hypertension, and lowering the UA level is no longer protective. 34 Prolonged hyperuricemia in rats also caused progressive renal injury via a crystalline-independent mechanism 33 and accelerated established renal disease. 35 Finally, UA stimulated synthesis of monocyte chemoattractant protein-1 by the rat vascular smooth muscle cells, 36 and this is known to stimulate macrophage infiltration of atherosclerotic vessels. 37 Apart from the interactions between UA and other risk factors in CVD, there are several other plausible mechanisms whereby UA may directly affect atherogenesis or the clinical course of cerebrovascular disease. Cerebral infarction initiates a complex cascade of metabolic events in the surrounding tissue, and free-radical-mediated oxidative damage plays a key role in the pathogenesis of cerebral ischemia. 38 Free radicals are liberated from a variety of sources, including inflammatory cells, dysfunctional mitochondria and excitotoxic mechanisms stimulated by increased glutamate and aspartate concentrations. 39 Hydroxyl radicals, peroxynitrite and superoxide, are powerful radicals that can cause lipid peroxidation, a self-propagating chain reaction, that irreversibly damages plasma and mitochondrial membranes. 40 Products of lipid peroxidation irreversibly disrupt enzymes, receptors, and membrane transport mechanisms. The generation of local oxidants augments local injury and increases infarct size. 38 Stroke is associated with a rapid decrease in serum antioxidants, 41, 42 and patients with lower plasma antioxidants at the time of acute stroke have a poorer outcome. 43 UA is the most abundant aqueous antioxidant in humans and contributes as much as twothirds of all the free radical scavenging capacity of plasma. It is particularly effective in quenching hydroxyl, superoxide and penoxynitrite radicals, and may serve a protective physiological role by preventing lipid peroxidation. 44 It might therefore be expected that having an elevated SUA level during an acute stroke would be beneficial. However, only 1 study has reported that high SUA levels may be neuroprotective in patients with acute stroke, resulting in better functional outcome at discharge, 45 whereas 3 other large series [24] [25] [26] and our study found the opposite. One explanation would be that UA, being an aqueous antioxidant, can become a pro-oxidant under certain circumstances, particularly if other antioxidants such as ascorbate are low. 46 Thus, in patients with acute stroke the fall in ascorbate levels could predispose the SUA to take on pro-oxidant properties. Consistent with this hypothesis is the observation that in acute stroke, those with high SUA and low ascorbate levels have the worst outcome. 25 Different studies support the hypothesis that hyperuricemia causes vascular disease via endothelial dysfunction. For example, direct infusion of UA into the human brachial artery caused endothelial dysfunction. 47 UA was also found to promote LDL-C oxidation in vitro 48 and to stimulate granulocyte adherence to the endothelium. 49 In addition, a consistent relationship between elevated SUA levels and circulating inflammatory markers has been reported. [50] [51] [52] Moreover, UA may accumulate as crystals within atherosclerotic plaques. 53 It has also been speculated that SUA might increase the risk of developing CVD through its association with the metabolic syndrome (MetS). [54] [55] [56] SUA levels are often increased in subjects with MetS. [57] [58] [59] Insulin resistance (IR) is probably the underlying condition triggering the development of both hyperuricemia and MetS and is directly related to SUA levels. 54, 60 In patients with MetS, IR and decreased insulin-induced UA excretion may account for the observed increase in UA levels. 54 In addition, IR may also be linked to increased purine biosynthesis and turnover, with its attendant increase in SUA levels. 54, 60 On the other hand, there is evidence that SUA may not only be a consequence of IR, but it may actually promote or worsen IR and thus play an important role in the pathogenesis of MetS, 61 possibly through its ability to disturb endothelial function and thus inhibit NO bioavailability. 47 Because insulin requires NO to stimulate glucose uptake, it has been hypothesized that hyperuricemia may have a key role in the pathogenesis of IR. 61 In addition, a strong relationship between hyperuricemia and the risk factors of MetS has been shown in recent large epidemiologic studies. 55, 58, 62 The relationship between SUA levels and MetS is of considerable importance, because almost one-third of middle-aged men and women in the United States have MetS, 63 whereas in Greece, the respective percentage is 24.5%, 64 Furthermore, MetS has recently been shown to represent a strong independent risk factor for ischemic stroke. [65] [66] [67] [68] In the present study, increased SUA levels strongly correlated with low HDL-C levels, one of the 5 diagnostic criteria of MetS. 69 Unfortunately, we cannot assess the prevalence of MetS in these patients because we did not determine waist circumference, a principal diagnostic criterion of MetS. 69 However, the prognostic value of increased SUA levels was independent of all the other criteria of MetS, namely blood pressure and HDL-C, glucose and triglyceride levels, pointing to a direct link between SUA levels and adverse outcome in acute stroke. 69 It is clear that more studies are needed to determine whether the SUA level increases the risk for CVD directly, or indirectly through its association with MetS.
A rather unexpected finding of this study was that, in the univariate analysis, lower levels of total cholesterol and the absence of hyperlipidemia was associated with the occurrence of death, particularly death from incident stroke and cardiovascular causes. In contrast, several prospective studies have showed that higher levels of total cholesterol increase the risk of ischemic stroke. 70, 71 Furthermore, a meta-analysis of 90,000 patients showed that administration of statins reduces the risk of stroke among patients with coronary heart disease and those at increased risk for CVD and that this risk reduction is primarily related to the extent to which LDL-C levels are lowered. 72 However, in the acute stroke setting, several studies have shown the opposite; that is, low cholesterol levels are associated with short-term mortality or worse functional outcome in patients with ischemic stroke, particularly in those who are older. [73] [74] [75] Several pos-sible explanations have been proposed to explain this apparent paradox, mainly the idea of selective mortality, which is a hypothesis that many individuals with high levels of total cholesterol might experience an earlier onset of severe coronary heart disease, leading to disproportionately greater mortality before reaching an advanced age. [76] [77] [78] It has also been argued that low cholesterol levels may reflect an underlying serious disease or poor nutritional status, which could predispose to a poor outcome after stroke. 76, [79] [80] [81] Indeed, previous studies have shown a graded negative relationship between serum cholesterol levels and the risk of nosocomial infections. 82 Finally, serum levels of total cholesterol are known to be negative acute phase reactants, and decrease after ischemic and hemorrhagic stroke, and might therefore reflect the severity of stroke. 76, 83, 84 However, in the present multivariate analysis, there was no association between low total cholesterol levels and increased mortality. Even more importantly, these findings in the acute stroke setting should not be misinterpreted as indicating that elevated cholesterol levels also confer longterm survival benefit in these patients. On the contrary, in patients with prior cerebrovascular disease, high levels of total cholesterol increase the risk of myocardial infarction, 85 whereas treatment with a statin reduces the incidence of major cardiovascular events in this population. 86, 87 In conclusion, this study demonstrated that a raised SUA level is an independent predictor of early death after acute stroke. Although traditional risk factors such as hypertension, diabetes mellitus and hyperlipidaemia are nowadays treated aggressively after stroke, there is a need to identify additional modifiable risk factors that can affect morbidity and mortality. In this context, it is noteworthy that, beyond allopurinol and the well-established uricosuric drugs, several other agents can decrease the SUA level, such as losartan and fenofibrate. 88 More importantly, we have shown that administration of statins significantly reduces SUA levels 89 and preserves renal function, 90 and these actions independently protect against vascular events in high-risk patients. 59 Thus, a reduction in SUA level could also partially contribute to the beneficial effects of statins against stroke. 72, 87 However, further prospective studies are required to identify the precise role of hyperuricemia in cerebrovascular disease before routine treatment of this potential risk factor can be recommended.
